Clinical Trials Logo

CLL/SLL clinical trials

View clinical trials related to CLL/SLL.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05365100 Withdrawn - NHL Clinical Trials

A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

Start date: July 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN102 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin's Lymphoma (NHL)

NCT ID: NCT05176691 Withdrawn - Follicular Lymphoma Clinical Trials

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Start date: February 15, 2022
Phase: Phase 1
Study type: Interventional

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL

NCT ID: NCT04694560 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Start date: December 22, 2020
Phase:
Study type: Observational

The purpose of this study is to find out whether people with CLL or SLL who are currently receiving treatment with ibrutinib can stop treatment and remain off-treatment for at least 12 months, if they have achieved complete or partial remission of their disease.

NCT ID: NCT04660045 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Early Intervention With Acalabrutinib in Patients With High Risk CLL

Start date: May 2022
Phase: Phase 2
Study type: Interventional

This study evaluates the effectiveness of acalabrutinib treatment in patients with chronic lymphocytic leukemia (CLL) deemed at high risk for Richter's Transformation (RT). This is a single arm study. Enrolled patients will initiate therapy with acalabrutinib and will dose continuously. While on study, subjects will be monitored monthly for the first 3 months, then every three months thereafter until disease progression, discontinuation due to toxicity, death, or study completion.